Bangladesh company offering cheap copy of Gilead's blockbuster hep C drug
Mumbai
A US$10 version of Sovaldi, the Gilead Sciences Inc hepatitis C treatment that sells for US$1,000 a pill in the US, is now available in Bangladesh and could make its way to other parts of the world where the US company doesn't have patents.
Incepta Pharmaceuticals Ltd doesn't have a licence from Gilead and its version was launched last month, said managing director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of South-east Asia and Africa.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action